Moderna GAAP EPS of $3.61 misses by $1.14, revenue of $5.1B beats by $80M
Moderna press release  (NASDAQ:MRNA): Q4  GAAP EPS of $3.61  misses by $1.14.
Revenue of $5.1B (-29.5% Y/Y)  beats by $80M.
Total revenue for the fourth quarter of 2022 was $5.1 billion, compared to $7.2 billion in the same period in 2021, mainly due to a decrease in sales of the Company's COVID-19 vaccines.
Product sales for the fourth quarter of 2022 were $4.9 billion, a decrease of 30% compared to the same period in 2021, primarily driven by lower sales volume, compared to overall higher demand in the prior year and the related manufacturing ramp up in the fourth quarter of 2021.